Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.

Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Gilmour B, Navarro H, Rothman RB, Prisinzano TE.

J Nat Prod. 2006 Jan;69(1):107-12.

2.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.

Simpson DS, Katavic PL, Lozama A, Harding WW, Parrish D, Deschamps JR, Dersch CM, Partilla JS, Rothman RB, Navarro H, Prisinzano TE.

J Med Chem. 2007 Jul 26;50(15):3596-603. Epub 2007 Jun 20.

PMID:
17580847
3.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.

Holden KG, Tidgewell K, Marquam A, Rothman RB, Navarro H, Prisinzano TE.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6111-5. Epub 2007 Sep 15.

4.

Synthesis of salvinorin A analogues as opioid receptor probes.

Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P, Dersch CM, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE.

J Nat Prod. 2006 Jun;69(6):914-8.

PMID:
16792410
5.

Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum.

Harding WW, Tidgewell K, Schmidt M, Shah K, Dersch CM, Snyder J, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE.

Org Lett. 2005 Jul 7;7(14):3017-20.

6.

Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.

Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE.

J Med Chem. 2005 Jul 28;48(15):4765-71.

PMID:
16033256
7.

Total synthesis of the hallucinogenic neoclerodane diterpenoid salvinorin A.

Nozawa M, Suka Y, Hoshi T, Suzuki T, Hagiwara H.

Org Lett. 2008 Apr 3;10(7):1365-8. doi: 10.1021/ol800101v. Epub 2008 Mar 1.

PMID:
18311991
8.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Simpson DS, Lovell KM, Lozama A, Han N, Day VW, Dersch CM, Rothman RB, Prisinzano TE.

Org Biomol Chem. 2009 Sep 21;7(18):3748-56. doi: 10.1039/b905148a. Epub 2009 Jul 14.

9.

New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.

Lee DY, Ma Z, Liu-Chen LY, Wang Y, Chen Y, Carlezon WA Jr, Cohen B.

Bioorg Med Chem. 2005 Oct 1;13(19):5635-9.

PMID:
16084728
10.

Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.

Fantegrossi WE, Kugle KM, Valdes LJ 3rd, Koreeda M, Woods JH.

Behav Pharmacol. 2005 Dec;16(8):627-33.

PMID:
16286814
11.

Divinatorins A-C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum.

Bigham AK, Munro TA, Rizzacasa MA, Robins-Browne RM.

J Nat Prod. 2003 Sep;66(9):1242-4.

PMID:
14510607
12.

Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL.

J Pharmacol Exp Ther. 2004 Mar;308(3):1197-203. Epub 2004 Jan 8.

13.

Palladium-catalyzed transformations of salvinorin A, a neoclerodane diterpene from Salvia divinorum.

Riley AP, Day VW, Navarro HA, Prisinzano TE.

Org Lett. 2013 Dec 6;15(23):5936-9. doi: 10.1021/ol4027528. Epub 2013 Nov 18.

14.

Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.

Polepally PR, White K, Vardy E, Roth BL, Ferreira D, Zjawiony JK.

Bioorg Med Chem Lett. 2013 May 15;23(10):2860-2. doi: 10.1016/j.bmcl.2013.03.111. Epub 2013 Apr 4.

15.

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11934-9. Epub 2002 Aug 21.

16.

Neo-clerodane diterpenes from the hallucinogenic sage Salvia divinorum.

Shirota O, Nagamatsu K, Sekita S.

J Nat Prod. 2006 Dec;69(12):1782-6. Erratum in: J Nat Prod. 2007 Feb;70(2):328.

PMID:
17190459
17.

From local to global-fifty years of research on Salvia divinorum.

Casselman I, Nock CJ, Wohlmuth H, Weatherby RP, Heinrich M.

J Ethnopharmacol. 2014 Feb 3;151(2):768-83. doi: 10.1016/j.jep.2013.11.032. Epub 2013 Dec 4. Review.

PMID:
24315983
18.

Salvinorins J from Salvia divinorum: mutarotation in the neoclerodane system.

Kutrzeba LM, Ferreira D, Zjawiony JK.

J Nat Prod. 2009 Jul;72(7):1361-3. doi: 10.1021/np900181q.

PMID:
19473009
19.

Salvinorin A: from natural product to human therapeutics.

Vortherms TA, Roth BL.

Mol Interv. 2006 Oct;6(5):257-65. Review.

PMID:
17035666
20.

A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.

Cruz A, Domingos S, Gallardo E, Martinho A.

Phytochemistry. 2017 May;137:9-14. doi: 10.1016/j.phytochem.2017.02.001. Epub 2017 Feb 10.

PMID:
28190678

Supplemental Content

Support Center